Pediatrix Medical Group layoffs, on the record
Every job cut, severance charge and restructuring Pediatrix Medical Group reported in its annual reports, 2023 to 2025, quoted from the filings.
Headcount, as reported
| Annual report | Employees | As of |
|---|---|---|
| 10-K for 2023 | approximately 2,900 other full-time and part-time employees | As of December 31, 2023 |
| 10-K for 2024 | approximately 2,150 other full-time and part-time employees | As of December 31, 2024 |
| 10-K for 2025 | approximately 2,260 other full-time and part-time employees | December 31, 2025 |
Job cuts, severance and restructuring
Our summaryCompany recorded transformational and restructuring related expenses of $2.2 million in 2023, tied to terminating its revenue cycle management vendor.
Word for word“During 2023, our transformation and restructuring related expenses relate specifically to the activities associated with the termination of our revenue cycle management vendor.” 10-K for 2023
Our summaryCompany's 2023 restructuring expenses decreased from 2022, reflecting lower position eliminations expense, contract termination costs and consulting fees.
Word for word“The decrease of $25.1 million reflects decreases in position eliminations expense, contract termination costs and consulting fees.” 10-K for 2023
Our summaryCompany launched strategic transformation and restructuring initiatives across shared services and operational infrastructure, including workstreams that involved position eliminations and executive and board restructuring.
Word for word“Beginning in 2019, we developed a number of strategic initiatives across our organization, in both our shared services functions and our operational infrastructure, with a goal of generating improvements in our general and administrative expenses and our operational infrastructure.” 10-K for 2023
Our summaryCompany recorded accelerated stock-based compensation expense related to certain position eliminations within restructuring expenses.
Word for word“This excludes accelerated stock-based compensation expense related to certain position eliminations that is included within transformational and restructuring related expenses.” 10-K for 2023
Our summaryCompany carried out practice portfolio management, revenue cycle management transition and position eliminations across shared services and operations, recording transformational and restructuring related expenses including lease impairment and severance.
Word for word“Transformational and restructuring related expenses were $64.3 million for the year ended December 31, 2024, as compared to $2.2 million for 2023.” 10-K for 2024
Our summaryCompany recorded an expense line for severance and lease impairment tied to position eliminations across various shared services and operations departments.
Word for word“The expenses during 2024 reflect lease impairment and severance expenses resulting from our practice portfolio management activities, revenue cycle management transition activities, and position eliminations across various shared services and operations departments.” 10-K for 2024
Our summaryCompany recorded fixed asset, operating lease right-of-use and intangible asset impairments tied to the planned exits of pediatric office-based practices, which were completed as of year end.
Word for word“As a result, we recorded fixed asset impairments of $20.1 million, operating lease right-of-use asset impairments of $12.5 million and intangible asset impairments of $7.7 million during the year ended December 31, 2024.” 10-K for 2024
Our summaryThe company recorded transformational and restructuring expenses in 2025, mainly for eliminating positions in shared services departments and for revenue cycle management transition activities.
Word for word“Transformational and restructuring related expenses were $22.3 million for the year ended December 31, 2025, as compared to $64.3 million for 2024.” 10-K for 2025
Our summaryThe company recognized additional stock-based compensation expense tied to restructuring in 2025 and 2024.
Word for word“In addition, during the years ended December 31, 2025 and 2024, the Company recognized an additional $ 6.3 million and $ 2.0 million, respectively, of stock-based compensation related restructuring expense, which is included in transformational and restructuring related expenses in the Consolidated Statements of Income and Comprehensive Income.” 10-K for 2025
| Fiscal year ended | Restructuring charges |
|---|---|
| 2017-12-31 | $0 |
| 2018-12-31 | $0 |
| 2019-12-31 | $60.9 million |
| 2020-12-31 | $73.8 million |
| 2021-12-31 | $22.1 million |
| 2022-12-31 | $27.3 million |
| 2023-12-31 | $2.2 million |
| 2024-12-31 | $64.3 million |
| 2025-12-31 | $22.3 million |
Pediatrix Medical Group has filed no restructuring notice (Form 8-K, Item 2.05) since 2016. Companies file one only for a cut they judge material, so many announced layoffs never appear as one. This page shows what the company reported to the SEC, not news reports or state layoff notices.
Read from Pediatrix Medical Group’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-19. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.